Format

Send to

Choose Destination
See comment in PubMed Commons below
Histopathology. 2013 Feb;62(3):499-504. doi: 10.1111/his.12021. Epub 2012 Nov 27.

BRAF V600E and KRAS G12S mutations in peripheral nerve sheath tumours.

Author information

1
Department of Oncology, Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Passeig de la Vall d’Hebron 119–129, Barcelona, Spain.

Abstract

AIMS:

Benign (BPNST) and malignant (MPNST) peripheral nerve sheath tumours occur either sporadically or are related to neurofibromatosis (NF). The mechanisms involved are well known in NF-related tumours, but still remain unclear in sporadic cases. Somatic BRAF and KRAS mutations represent the most frequent genetic events in melanocytic neoplastic lesions. Because melanocytes and Schwann cells both derive from neural crest cells, we hypothesized that BRAF and KRAS mutations might influence BPNST and MPNST development.

METHODS AND RESULTS:

BRAF exon 15 and KRAS exons 2 and 3 polymerase chain reaction (PCR) sequencing was performed in formalin-fixed/paraffin-embedded samples of 99 BPNST and MPNST, related and non-related to NF types 1 and 2. Oncogenic BRAF V600E mutations were found in four of 40 schwannomas (including one acoustic neuroma) and one of 13 MPNST, not associated with NF. A KRAS G12S mutation was also evident in one sporadic schwannoma.

CONCLUSION:

Our findings suggest that RAS pathway activation due to BRAF V600E and KRAS mutations is an important event in a subset of peripheral nerve sheath tumours not related to NF.

PMID:
23190154
DOI:
10.1111/his.12021
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center